Liu, Joyce F <br/><br/>
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?  [electronic resource] 

 -  Current oncology reports  May 2016 
 - 29 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1534-6269 
<br/><br/><label>Standard No.: </label>10.1007/s11912-016-0515-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Mutation<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Poly(ADP-ribose) Polymerase Inhibitors--administration & dosage